Relapsed Leukemia and Lymphoma Program News

Our team includes international leaders in leukemia and lymphoma treatment. Because we have treated so many children — including children who have come to us from around the world — we have a deep familiarity with this type of cancer.

How we serve you

Existing patients or family members

215-590-3025

New patients, referrals and second opinions

267-426-0762

New Study Shows AML Ages Immune Cells, Leading to Poor Treatment Response

Nov 28, 2022

A new study has found that acute myeloid leukemia (AML) ages and exhausts immune cells, impairing their ability to fight off cancer.

CHOP Researchers Develop Allogeneic CART for Relapsed or Refractory T-ALL Using Base Editing

May 23, 2022

CHOP researchers have tested and developed an “off-the-shelf” chimeric antigen receptor T-cell (CART) using base editing.

CHOP Brings Together Experts to Discuss Precision Medicine in Pediatric Cancer Care

Mar 18, 2022

More than 250 experts gathered in Philadelphia and virtually to discuss the latest scientific advancements and breakthroughs in pediatric precision medicine oncology.

CHOP-Led Study Finds Bortezomib Improves Survival in Children with Newly Diagnosed T-Cell Lymphoblastic Lymphoma

Mar 10, 2022

In a COG trial, CHOP researchers found adding bortezomib to chemotherapy significantly improved overall survival in children and young adults with newly diagnosed T-cell lymphoblastic lymphoma (T-LL).

CHOP Researchers Develop Humanized CAR T-Cell Therapy that Shows Potential for Patients with Relapsed B-ALL

Jun 28, 2021

The treatment modifies a domain in the CAR that targets CD19, making it look more human and therefore less likely to be rejected by patients.

AML Immunotherapy Trial Opens

Jan 23, 2020

CHOP has opened a phase 1 trial using CAR T for tough acute myeloid leukemia, hoping to replicate the therapy’s success for acute lymphoblastic leukemia.

Humanized CD19: CAR-T Immunotherapy for First Relapse of ALL in Down Syndrome Patient

Jan 11, 2019

An alternative, humanized CD19 CAR T product for first relapse of pediatric ALL is being evaluated in a clinical trial at Children's Hospital of Philadelphia.

Photograph of an acute lymphoblastic leukemia cell

CHOP Scientists Report How Some Cancer Cells Develop Resistance to CAR T-cell Therapy

Nov 27, 2018

CHOP researchers analyze how some cancer cells resist a groundbreaking cellular therapy, and have found clues to overcoming that resistance.

Immunotherapy: What’s Next for CAR-T Therapy

Jan 24, 2019

Trials of more game-changing cell therapies for pediatric cancer and other diseases are underway or on the horizon at Children's Hospital of Philadelphia.

Parents Magazine Names Children’s Hospital of Philadelphia Among 20 Most Innovative Children’s Hospitals

Sep 5, 2018

Children’s Hospital of Philadelphia was recognized specifically for significant contributions to the development of a new treatment for a certain pediatric leukemia.

Find a research study

Innovation and your child

Find research studies